Skip to content
Portage Biotech
Portage BiotechPortage Biotech
  • about us
    • overview
    • leadership
  • our pipeline
    • iNKT platform
    • adenosine platform
    • other programs in development
  • investors
    • overview
    • stock information
    • news releases
    • investor calendar
    • presentations & publications
    • sec filings
    • financial & regulatory reports
    • corporate governance
    • investor faqs
  • join our team
  • contact
  • about us
    • overview
    • leadership
  • our pipeline
    • iNKT platform
    • adenosine platform
    • other programs in development
  • investors
    • overview
    • stock information
    • news releases
    • investor calendar
    • presentations & publications
    • sec filings
    • financial & regulatory reports
    • corporate governance
    • investor faqs
  • join our team
  • contact

Daily Archives: April 8, 2021

Portage Biotech Begins Phase I Trial of Invariant Natural Killer T-Cell Therapy

Media CoverageBy walidApril 8, 2021
...

Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors

Press ReleaseBy Portage Biotech, IncApril 8, 2021
...
Copyright © All rights reserved Portage Biotech, Inc

terms of use   privacy policy   disclaimer

Go to Top